Abstract

Introduction: The aim of this work is to establish a novel, simple, precise and sensitive UV-AUC spectrophotometry method for estimation of Pyrazinamide from bulk and in-Pharmaceutical formulation and validate it according ICH guidelines. Pyrazinamide is used for the treatment of tuberculosis.

Methods and Methodology: Pyrazinamide was estimated by four simple UV-Spectrophotometric methods using double beam UV- Spectrophotometer (UV-2450, Shimadzu). A stock standard solution was prepared by dissolving 10 mg of Pyrazinamide in to 100 mL volumetric flask then volume was made by methanol up to the mark, the obtaining concentration was 100µg/mL. After suitable dilutions, it scans in the UV-visible range 200 - 400 nm. For Method A and Method B zero-order spectrum and area under curve (AUC) recorded at 268 nm and 259.40 - 273.20 nm respectively. While for Method C and for Method D first-order derivative the amplitude and area under curve (AUC) recorded at 279nm and 277.20 - 282.60 nm respectively. For linearity study, series of dilutions were prepared from stock solutions.

Results: In Method A, B, C and Method D, Pyrazinamide followed linearity in the concentration range of 2 - 12 μg/mL with (r² > 0.999). The % recovery was found to be in the range of 98 - 102%. Furthermore, the precision of methods were calculated in terms of % RSD less than 2 showed, methods are precise. The developed methods was validate according to ICH guidelines.

Conclusion: The developed methods are simple, rugged, robust and economical. The illustrated methods can routinely be used for determination of Pyrazinamide in bulk and in Pharmaceutical formulation.

Keywords: Area Under Curve Spectrophotometry; Derivative-Spectrophotometry; Pyrazinamide

References

1. www.Drugbank.com
2. S Budavari. ‘‘The Merck Index”. an Encyclopedia of Chemicals, Drugs and Biological, 15^th Edition, Merck and Co., Inc., White House Station, NJ (2013).
3. Martindale-extra pharmacopeia, The complete drug reference, 38^th Edition. The Pharmaceutical Press, London, UK (2014).
4. Dalal A., et al. “HPLC Method development for determination of pyrazinamide and related substance by using quality by design (QBD) approach”. European Chemical Bulletin 8.10 (2019): 328-334.
5. Bozorg B., et al. “Simultaneous determination of isoniazide, pyrazinamide and rifampin in human plasma by high-performance liquid chromatography and UV detection”. Iranian Journal of Pharmaceutical Research 18.4 (2019): 1735-1741.
6. Chellini PR., et al. “Development and Validation of an HPLC Method for Simultaneous Determination of Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol Hydrochloride in Pharmaceutical Formulations”. Journal of AOAC International 98.5 (2015).
7. Assali M., et al. “RP-HPLC Method Development and Validation of Synthesized Codrug in Combination with Indomethacin, Paracetamol, and Famotidine”. Hindawi International Journal of Analytical Chemistry (2020): 1-9.
8. Momin MA., et al. “Development and validation of a RP-HPLC method for simultaneous quantification of bedaquiline (TMC207), moxifloxacin and pyrazinamide in a pharmaceutical powder formulation for inhalation”. Journal of Liquid Chromatography and Related Technologies (2018). 
9. Arige SD and Rao L. “Rp-hplc method development and validation for simultaneous estimation of isoniazid and pyrazinamide”. International Journal of Applied Pharmaceutical Science 5 (2017): 1-11.
10. Prasanthia B., et al. “Development and Validation of RPHPLC Method for Simultaneous Estimation of Rifampicin, Isoniazid and Pyrazinamide in Human Plasma”. Journal of Analytical Chemistry 70.8 (2015): 1015-1022. 
11. Luyen L., et al. “Simultaneous Determination of Pyrazinamide, Rifampicin, Ethambutol, Isoniazid and Acetyl Isoniazid in Human Plasma by LC-MS/MS Method”. Journal of Applied Pharmaceutical Science 8.9 (2018): 061-073.
12. Chaitanya Krishna A., et al. “Determination of pyrazinamide in human plasma samples containing fixed dose combination molecules by using liquid chromatography tandem mass spectrometry”. Advances in Pharmacoepidemiology and Drug Safety 1.10 (2012): 2. 
13. Zhifeng Z., et al. “Development and validation of a hydrophilic interaction liquid chromatography–tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma”. Analytical and Bioanalytical Chemistry 405 (2013): 6323-6365. 
14. Habib N., et al. “Different spectrophotometric and TLC-densitometric methods for determination of pyrazinamide in presence of its impurity”. Bulletin of Faculty of Pharmacy, Cairo University (2017).
15. Khawas S., et al. “Simultaneous Spectrophotometric estimation of rifampicin, isoniazid and pyrazinamide in their pharmaceutical dosage form”. Asian Journal of Research in Chemistry 13 (2020): 117-122.
16. Khan MF., et al. “Theoretically guided analytical method development and validation for the estimation of rifampicin in a mixture of isoniazid and pyrazinamide by UV spectrophotometer”. Frontiers in Chemistry 5 (2017): 27.
17. Mohamed A., et al. “A novel spectrofluorimetric determination of four anti-TB drugs in their pure and pharmaceuticaldosage forms by quenching effect on the fluorescence of NBS-phenothiazine product”. Asian Journal of Biomedical and Pharmaceutical Sciences 3.26 (2013): 21-27.
18. International Conference on Harmonization (ICH), Q2A: Text on Validation of Analytical Procedure USFDA federal register 60 (1995): 11260.
19. Sharma BK. Instrumental Method of Chemical Analysis, 21^st edition, Goel Publishing Housing 3 (2002): 40.
20. Patil CV and Patil PA. “Development of validation of zero order, first order, second- order, UV- spectrophotometry methods using AUC technique for quantitative estimation of linagliptin in bulk material and tablets”. Asian Journal of Research in Chemistry 13.3 (2020): 228-230.

Citation

Citation: PS Jain., et al. “Development and Validation of Zero and First Order Derivative Area Under Curve Spectrophotometric Methods for Pyrazinamide in Bulk Material and Pharmaceutical Formulation". Acta Scientific Pharmaceutical Sciences 4.9 (2020): 48-55.

Copyright

Copyright: © 2020 PS Jain., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.